Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK joins the scheme as a Drug Discovery and Development Expert

Andy Pearce

The Business Development Team for the Medical Sciences Division has announced the appointment of a new  expert to its Industry Experts in Residence Scheme. Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK, joined the scheme in October. 

In his role Dr Pearce leads drug discovery projects from target validation through hit-finding and to the delivery of high quality clinical candidates, across broad disease areas, in collaboration with world-leading academic partners. He is a biochemist and cell biologist by training, and received his undergraduate degree and DPhil from the University of Oxford before undertaking postdoctoral studies at the University of Birmingham. Dr Pearce is a Fellow of the Royal Society of Biology, and he occasionally lectures at Oxford and Cambridge Universities and participates in career panels and workshops for scientists.

Dr Pearce said: ‘I am really excited to be taking up the position of Expert in Residence in Drug Discovery and Development. I am looking forward to meeting Oxford colleagues, discussing some of their great science, and contributing whatever I can to help advance Translational Research in Oxford towards medicines to benefit patients’.

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars given by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Pearce has made his expertise in Drug Discovery and Development available to researchers. Dr Pearce will sit in the Target Discovery Institute (TDI), Nuffield Department of Medicine, NDM Research Building on various dates during 2018/19. If you would like to arrange a meeting please contact charlotte.bell@medsci.ox.ac.uk

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.

'Find out more about the scheme and book an appointment with an expert 

Similar stories

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Awards and Appointments General Innovation Research

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

General Innovation

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies

General Innovation

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.